| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Michael Pillinger | Q50129009 |
| Binita Shah | Q84282392 | ||
| Anastasia Slobodnick | Q85650355 | ||
| P2093 | author name string | Svetlana Krasnokutsky | |
| P2860 | cites work | EULAR recommendations for the management of familial Mediterranean fever | Q26775286 |
| Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis | Q27000643 | ||
| Colchicine--Update on mechanisms of action and therapeutic uses | Q28082473 | ||
| Gout-associated uric acid crystals activate the NALP3 inflammasome | Q28131797 | ||
| 2016 updated EULAR evidence-based recommendations for the management of gout | Q30248787 | ||
| Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials | Q33830317 | ||
| Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis | Q33875514 | ||
| Colchicine for familial Mediterranean fever | Q34052599 | ||
| Genetic loss of murine pyrin, the Familial Mediterranean Fever protein, increases interleukin-1β levels | Q34506303 | ||
| Febuxostat compared with allopurinol in patients with hyperuricemia and gout | Q34563183 | ||
| Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance | Q34592657 | ||
| EULAR recommendations for calcium pyrophosphate deposition. Part II: management. | Q34626526 | ||
| Colchicine prophylaxis in pseudogout | Q34692251 | ||
| Tubulin bound to colchicine forms polymers different from microtubules | Q36319837 | ||
| Colchicine: old and new | Q36384995 | ||
| Effect of Colchicine on Platelet-Platelet and Platelet-Leukocyte Interactions: a Pilot Study in Healthy Subjects | Q36578681 | ||
| Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement | Q36714926 | ||
| 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis | Q36870924 | ||
| Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. | Q37070180 | ||
| Colchicine: its mechanism of action and efficacy in crystal-induced inflammation | Q37220559 | ||
| How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? | Q37280787 | ||
| Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims | Q37308677 | ||
| Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report | Q37555163 | ||
| Unrecognized fatalities related to colchicine in hospitalized patients. | Q37899163 | ||
| Safety profile of anti-gout agents: an update | Q38174813 | ||
| Acute colchicine overdose: report of three cases. | Q38202484 | ||
| Pharmacokinetics considerations for gout treatments | Q38210284 | ||
| Mechanism of action of colchicine in the treatment of gout | Q38242695 | ||
| Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study | Q38406030 | ||
| GOSPEL 2 - Colchicine for the treatment of gout flares in France - a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age. | Q39176059 | ||
| Does colchicine work? The results of the first controlled study in acute gout. | Q39537644 | ||
| Cardiovascular Disease Prevalence in Patients with Osteoarthritis, Gout, or Both | Q39696658 | ||
| Colchicine toxicity in renal patients - Are we paying attention? | Q40144170 | ||
| Relationship between response to colchicine treatment and MDR1 polymorphism in familial Mediterranean fever patients | Q40229718 | ||
| Technical advance: Inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments | Q40239704 | ||
| Prevention of amyloidosis in familial Mediterranean fever with colchicine: a case-control study in Armenia | Q40378286 | ||
| Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. | Q40445405 | ||
| Colchicine neuromyopathy: a report of six cases. | Q40573266 | ||
| The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. | Q40621671 | ||
| Long-term colchicine treatment in children with familial mediterranean fever | Q40746167 | ||
| Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years | Q40751866 | ||
| Colchicine in Familial Mediterranean Fever | Q40891890 | ||
| Inhibition of LPS-induced tumor necrosis factor-alpha production by colchicine and other microtubule disrupting drugs | Q41160906 | ||
| Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine | Q42123133 | ||
| Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors | Q42168863 | ||
| Colchicine myopathy and neuropathy | Q42206597 | ||
| Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils | Q42929472 | ||
| High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study | Q43174058 | ||
| Occupancy approach to colchicine dosage | Q43529207 | ||
| A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee | Q43957154 | ||
| Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin | Q44200711 | ||
| Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial | Q44762080 | ||
| Cytoskeletal myotoxicity from simvastatin and colchicine | Q45076336 | ||
| Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis | Q45167250 | ||
| Low-dose colchicine for secondary prevention of cardiovascular disease | Q46245044 | ||
| Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study | Q46593124 | ||
| Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine | Q46961985 | ||
| Risk of myocardial infarction among patients with gout: a nationwide population-based study. | Q47393756 | ||
| Colchicine--a short history of an ancient drug | Q47578209 | ||
| The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. | Q51072106 | ||
| Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions. | Q51328148 | ||
| Gout Is a Chronic Inflammatory Disease in Which High Levels of Interleukin-8 (CXCL8), Myeloid-Related Protein 8/Myeloid-Related Protein 14 Complex, and an Altered Proteome Are Associated With Diabetes Mellitus and Cardiovascular Disease | Q53590616 | ||
| Long-term colchicine prophylaxis in familial Mediterranean fever | Q67692370 | ||
| Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever | Q68122991 | ||
| Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients | Q69357321 | ||
| Effect of synthetic calcium pyrophosphate and hydroxyapatite crystals on the interaction of human blood mononuclear cells with chondrocytes, synovial cells, and fibroblasts | Q69818728 | ||
| Intravenous colchicine in the treatment of acute pseudogout | Q71154436 | ||
| Colchicine and pseudogout | Q71326064 | ||
| Colchicine toxicity in patients with chronic renal failure | Q71779090 | ||
| Colchicine and HMG Co-A reductase inhibitors induced myopathy-a case report | Q79268756 | ||
| Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury | Q83333586 | ||
| Rhabdomyolysis in a patient treated with colchicine and atorvastatin | Q83986457 | ||
| Are dosing adjustments required for colchicine in the elderly compared with younger patients? | Q84510254 | ||
| Myopathy and possible intestinal dysfunction in a patient treated with colchicine and simvastatin | Q85003817 | ||
| Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease | Q85938934 | ||
| Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction | Q87859589 | ||
| Prevention of acute attacks of pseudogout with oral colchicine | Q93539273 | ||
| P433 | issue | suppl_1 | |
| P921 | main subject | (S)-(−)-colchicine | Q326224 |
| P304 | page(s) | i4-i11 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | Update on colchicine, 2017 | |
| P478 | volume | 57 |
| Q99240141 | A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges |
| Q98936115 | Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates |
| Q94447061 | Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) |
| Q93232759 | Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel |
| Q92256742 | Inflammation as a Therapeutic Target in Atherosclerosis |
| Q91639388 | Novel Deleterious nsSNPs within MEFV Gene that Could Be Used as Diagnostic Markers to Predict Hereditary Familial Mediterranean Fever: Using Bioinformatics Analysis |
| Q95262726 | Psychopharmacology of COVID-19 |
| Q64096431 | State of care for patients with systemic autoinflammatory diseases - Results of a tertiary care survey |
| Q92128110 | The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 |
| Q95272715 | [Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients] |
Search more.